Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Public ClinicalTrials.gov record NCT04310592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
Study identification
- NCT ID
- NCT04310592
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celularity Incorporated
- Industry
- Enrollment
- 27 participants
Conditions and interventions
Conditions
- Alkylating Agents
- Analgesics
- Analgesics, Non-narcotic
- Anti-infective Agents
- Antimetabolites, Antineoplastic
- Antiviral Agents
- Hematologic Diseases
- Hematologic Neoplasms
- Immunologic Factors
- Immunosuppressive Agents
- Leukemia
- Leukemia in Remission
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Neoplasms
- Neoplasms by Histologic Type
- Peripheral Nervous System Agents
- Physiological Effects of Drugs
- Refractory AML
- Relapsed Adult AML
Interventions
- CYNK-001 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 11, 2020
- Primary completion
- Jan 19, 2023
- Completion
- Apr 27, 2023
- Last update posted
- Dec 11, 2024
2020 – 2023
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | — |
| Columbia University and New York Presbyterian Hospital | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Westchester Medical Center | Valhalla | New York | 10595 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Swedish Health Services | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04310592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 11, 2024 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04310592 live on ClinicalTrials.gov.